drugset
drugset / Trial / NCT07514975

First-In-Human Study of KHN922 for Injection

NCT07514975 ↗

Phase 1/2 Not yet recruiting 276 enrolled Chengdu Kanghong Biotech Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors

Timeline

Start
2026-04
Primary completion
2028-04
Completion
2029-04

Drugs

EvaluationDrugModalityDoseRoute
Subject KHN922 Unknown 0.8 mg/kg Intravenous
Subject KHN922 Unknown 8 mg/kg Intravenous

Indications

No indication recorded.